Clinical reviews

SGLT2 INHIBITORS AND RISK OF DISTANT METASTASIS IN PATIENTS WITH BREAST CANCER AND TYPE 2 DIABETES: A TARGET TRIAL EMULATION WITH BIOLOGICAL PLAUSIBILITY ANALYSIS

Tri-Service General Hospital, College of Medicine, National Defense Medical University, Taipei, Taiwan

PDF15 pages1.7 MB

The research focuses on the potential anticancer properties of SGLT2 inhibitors beyond their glucose-lowering effects. It utilizes data from the TriNetX Global Collaborative Network, analyzing adult women with breast cancer who initiated SGLT2 inhibitors post-mastectomy. The study aims to determine whether these medications are associated with a reduced risk of distant metastasis, employing a propensity score matching approach to ensure comparability between groups.

Ask this resource

Answers use this document only.

Your first question is free.

More like this

Resources from the same specialty and type. Curated links will replace these when added.